Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger
Open Access
- 1 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (6) , 750-755
Abstract
Background. 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are effective for the induction and maintenance of remission and reduction of corticosterKeywords
This publication has 20 references indexed in Scilit:
- Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohnʼs disease: A cautionary tale?Inflammatory Bowel Diseases, 2007
- Relationship Between 6-Mercaptopurine Dose and 6-Thioguanine Nucleotide Levels in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2007
- Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-AnalysisGastroenterology, 2006
- Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter ExperienceJournal of Pediatric Gastroenterology and Nutrition, 2005
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseGut, 2001
- Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel diseaseGut, 2001
- Rational dosing of azathioprine and 6-mercaptopurineGut, 2001
- A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's diseaseGastroenterology, 2000
- Azathioprine and 6-Mercaptopurine in Crohn DiseaseAnnals of Internal Medicine, 1995
- The clinical pharmacology of 6-mercaptopurineEuropean Journal of Clinical Pharmacology, 1992